Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$8.94 USD
+0.19 (2.17%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $8.95 +0.01 (0.11%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.94 USD
+0.19 (2.17%)
Updated Nov 8, 2024 04:00 PM ET
After-Market: $8.95 +0.01 (0.11%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Zacks News
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
PTC Therapeutics (PTCT) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of 9.74% and 13.41%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Karyopharm Therapeutics (KPTI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 3.70% and 2.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?
by Zacks Equity Research
Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance Bio (TBPH) Up 2.2% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance (TBPH) Q2 Loss Wider Than Expected, Revenues Rise Y/Y
by Zacks Equity Research
Theravance (TBPH) misses second-quarter estimates on both fronts. Increased collaboration revenues from Viatris drive year-over-year top-line performance.
Theravance Biopharma (TBPH) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of -44.44% and 9.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Best Momentum Stocks to Buy for July 15th
by Zacks Equity Research
TBPH, HGV, and SPT made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 15, 2024.
New Strong Buy Stocks for July 15th
by Zacks Equity Research
TEF, AY, CQP, TBPH, and VIRC have been added to the Zacks Rank #1 (Strong Buy) List on July 15, 2024.
AstraZeneca's (AZN) Imfinzi Meets Study Goal in Bladder Cancer
by Zacks Equity Research
Data from a late-stage study shows that treatment with AstraZeneca's (AZN) Imfinzi plus chemotherapy before and after bladder removal surgery improves survival in patients.
Here's Why You May Invest in Theravance (TBPH) Stock Now
by Zacks Equity Research
Here, we discuss some reasons why investing in Theravance (TBPH) stock now may turn out to be a prudent move.
Wall Street Analysts Predict a 90.53% Upside in Theravance Bio (TBPH): Here's What You Should Know
by Zacks Equity Research
The mean of analysts' price targets for Theravance Bio (TBPH) points to a 90.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Theravance Bio (TBPH) Down 6.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance (TBPH) Q1 Earnings Top, Revenues Match Estimates
by Zacks Equity Research
Theravance's (TBPH) first-quarter 2024 earnings beat estimates while revenues meet the same.
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 52.63% and 0.25%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Catalent (CTLT) delivered earnings and revenue surprises of -125% and 3.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
by Zacks Equity Research
Theravance Bio (TBPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Theravance Bio (TBPH) Down 9% Since Last Earnings Report?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance's (TBPH) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Theravance's (TBPH) fourth-quarter earnings and revenues beat estimates. The company achieves profitability on an adjusted basis during the same time. Stock rises.
Theravance Biopharma (TBPH) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Theravance Bio (TBPH) delivered earnings and revenue surprises of 175% and 0.43%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Amylyx Pharmaceuticals, Inc. (AMLX) Misses Q4 Earnings Estimates
by Zacks Equity Research
Amylyx Pharmaceuticals, Inc. (AMLX) delivered earnings and revenue surprises of -65% and 1.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Down -11.17% in 4 Weeks, Here's Why Theravance Bio (TBPH) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Theravance Bio (TBPH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Theravance Bio (TBPH) Up 2.5% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Theravance Bio (TBPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Theravance's (TBPH) Q3 Loss Narrows, Revenues Beat Marginally
by Zacks Equity Research
Thervance (TBPH) incurs a narrower-than-expected loss in the third quarter of 2023. Revenues marginally beat estimates.